The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in taxane-refractory prostate cancer.
Daniel Peter Petrylak
No relevant relationships to disclose
Philip W. Kantoff
No relevant relationships to disclose
Yakov Rotshteyn
No relevant relationships to disclose
Robert Joseph Israel
No relevant relationships to disclose
William C. Olson
No relevant relationships to disclose
Tage Ramakrishna
No relevant relationships to disclose
Stephen Morris
No relevant relationships to disclose